Discovery of potential ALK inhibitors by virtual screening approach

Crizotinib is an anticancer drug used for the treatment of non-small cell lung cancer. Evidences available suggest that there is a development of an acquired resistance against crizotinib action due to the emergence of several mutations in the ALK gene. It is therefore necessary to develop potent an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Anish, Shanthi, V., Ramanathan, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706832/
https://www.ncbi.nlm.nih.gov/pubmed/28330089
http://dx.doi.org/10.1007/s13205-015-0336-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706832/
https://www.ncbi.nlm.nih.gov/pubmed/28330089
http://dx.doi.org/10.1007/s13205-015-0336-z

Ejemplares similares